Alerts will be sent to your verified email
Verify Email
BERLDRG
|
Beryl Drugs
|
Emmessar Biotech&Nut
|
Parmax Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
2.54 % | 13.7 % | -1624.87 % |
|
5yr Avg Net Profit Margin
|
0.66 % | 71.53 % | -9.48 % |
|
Price to Book
|
1.37 | 1.82 | 0.0 |
|
P/E
|
58.69 | 34.15 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-619.24 Days | 68.18 Days | -161.05 Days |
|
5yr Average Interest Coverage Ratio
|
1.68 | 815.2 | 1.16 |
|
5yr Avg ROCE
|
5.73 % | 19.97 % | -9.94 % |
|
5yr Avg Operating Profit Margin
|
7.19 % | -101.39 % | 3.93 % |
|
5 yr average Debt to Equity
|
0.64 | 0.0 | 17.42 |
|
5yr CAGR Net Profit
|
72.78 % | 0.0 | n/a |
|
5yr Average Return on Assets
|
1.31 % | 10.86 % | -6.43 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
26.38 % | 59.53 % | 30.8 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
1.46 % | 1.34 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Beryl Drugs
|
Emmessar Biotech&Nut
|
Parmax Pharma
|
|---|